Multinational observational study of safety and effectiveness of taxanes after radium-223 for metastatic castration-resistant prostate cancer

Radium-223 and taxane chemotherapy each improve survival of patients with metastatic castration-resistant prostate cancer (mCRPC). The multinational real-world observational REASSURE study evaluated taxane after radium-223 for mCRPC. Following radium-223 therapy, 182 patients received docetaxel and/or cabazitaxel; 73 patients received the taxanes within 90 days of the last radium-223 dose and 109 patients received the taxanes after longer than 90 days. Fourteen patients (7.7%) had grade 3 or 4 hematologic events during taxane chemotherapy. Median overall survival was 24.3 months from radium-223 initiation and 11.8 months from start of taxane therapy. The authors conclude that in real-world clinical practice settings, a heterogeneous population of mCRPC patients who received taxanes after radium-223 had a low incidence of hematologic events, with a median survival of 1 year from taxane initiation. Taxane chemotherapy is a feasible option for patients who progress after radium-223 (graphical abstract).